Check for updates

OPEN ACCESS

EDITED BY Can Aksu, Kocaeli University, Türkiye

REVIEWED BY Ece Yamak Altinpulluk, Morphological Madrid Research Center, Spain Huseyin Kemal Rasa, Anadolu Medcal Center Hospital, Türkiye

*CORRESPONDENCE Dereje Zewdu ⊠ Derejezewdu1529@gmail.com Temesgen Tantu ⊠ tematantu405@gmail.com

RECEIVED 11 March 2024 ACCEPTED 11 July 2024 PUBLISHED 29 July 2024

CITATION

Zewdu D, Tantu T, Eanga S and Tilahun T (2024) Analgesic efficacy of erector spinae plane block versus transversus abdominis plane block for laparoscopic cholecystectomy: a systematic review and meta-analysis of randomized controlled trial. *Front. Med.* 11:1399253. doi: 10.3389/fmed.2024.1399253

COPYRIGHT

© 2024 Zewdu, Tantu, Eanga and Tilahun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Analgesic efficacy of erector spinae plane block versus transversus abdominis plane block for laparoscopic cholecystectomy: a systematic review and meta-analysis of randomized controlled trial

Dereje Zewdu^{1*}, Temesgen Tantu^{2*}, Shamil Eanga¹ and Tamiru Tilahun¹

¹Department of Anesthesia, College of Medicine and Health Science, Wolkite University, Wolkite, Ethiopia, ²Department of Obstetrics and Gynecology, College of Medicine and Health Science, Wolkite University, Wolkite, Ethiopia

Background: Although laparoscopic cholecystectomy (LC) is a minimally invasive surgery, it can cause moderate to severe postoperative pain. Erector spinae plane (ESP) and transversus abdominis plane (TAP) blocks are considered effective means for pain management in such cases; however, there is inconclusive evidence regarding their analgesic efficacy. This meta-analysis aimed to compare the efficacy of ESP block and TAP block for pain control in LC.

Methods: We systematically searched Medline, PubMed, Scopus, Embase, and Google Scholar until 26 January 2024. All randomized clinical trials compared the efficacy of erector spinae plane block (ESPB) and transversus abdominis plane block (TAPB) for postoperative pain relief after LC. The primary outcomes were pain scores at rest and on movement at 1, 2, 6, 12, and 24 h postoperatively. The secondary outcomes were total opioid consumption, first analgesia request time, and rates of postoperative nausea and vomiting. We analyzed all the data using RevMan 5.4.

Results: A total of 8 RCTs, involving 542 patients (271 in the ESPB group and 271 in the TAPB group), were included in the analysis. The ESP block demonstrated statistically significant lower pain scores at rest and on movement than the TAP block at all-time points except at the 1st and 6th h on movement postoperatively; however, these differences were not considered clinically significant. Additionally, patients who received the ESP block required less morphine and had a longer time before requesting their first dose of analgesia. There were no significant differences in postoperative nausea and vomiting incidence between the two groups.

Conclusion: In patients undergoing LC, there is moderate evidence to suggest that the ESP block is effective in reducing pain severity, morphine equivalent consumption, and the time before the first analgesia request when compared to the TAP block during the early postoperative period.

Systematic review registration: PROSPERO CRD42024505635, https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024505635.

KEYWORDS

erector spinae plane block, transversus abdominis plane block, laparoscopic cholecystectomy, postoperative analgesia, nerve block analgesia

1 Introduction

Laparoscopic cholecystectomy (LC) is a frequently performed abdominal surgery. Although LC is less invasive and results in less postoperative pain than open cholecystectomy, it is not a pain-free procedure (1).

The fact that postoperative pain after LC is clinically significant is due to multiple sources of pain: visceral pain from gallbladder resection and peritoneal CO2 insufflation, and somatic pain from skin incisions (2, 3). Given this, providing proper pain management following LC is crucial, as poorly managed pain can lead to a range of complications, including prolonged hospital stays, readmissions, chronic postoperative pain, and persistent opioid use (4–6). Therefore, it is crucial to prioritize effective and safe pain management to improve postoperative outcomes in such cases.

Postsurgical pain management has been a topic of interest and controversy for many years. Several modalities are implemented into clinical practice to control postsurgical pain after LC, including patient-controlled analgesia, systemic opioids, and incision site infiltrations using local anesthetics and adjuvants (7–11). Although these methods have a proven analgesic advantage, their clinical significance remains uncertain due to their adverse effects, such as nausea, vomiting, respiratory depression, and urinary retention (11, 12).

Ultrasound-guided truncal blocks, such as transversus abdominis plane (TAP) and erector spinae plane blocks (ESPB), reportedly reduce the severity of postoperative pain and are effective alternatives to decrease cumulative opioid consumption and manage perioperative pain using multimodal analgesia in such cases (13–15).

Currently, ongoing meta-analyses (16, 17) are comparing the effectiveness of a transversus abdominis plane (TAP) block and an erector spinae plane (ESP) block to a placebo. The results of these analyses have shown that both the TAP block and the ESP block provide superior analgesia and reduce postoperative opioid consumption following laparoscopic cholecystectomy (LC). However, recent randomized clinical trials (18-25) have presented conflicting results when comparing the postoperative analgesic efficacy of ESP and TAP blocks after LC. While some studies have demonstrated the superior pain-relieving effects of the ESP block, others have reported no significant difference between the two treatment groups. Additionally, a recent review (26) compared the analgesic efficacy of ESP and TAP blocks after abdominal surgeries. However, the review had a main limitation: it included a range of surgical procedures that could result in varied pain intensity and anatomical differences, leading to significant heterogeneity.

Nevertheless, no trials have comprehensively analyzed the available data to compare the pain relief effectiveness of ESP and TAP blocks following LC. Therefore, we conducted a meta-analysis to assess the efficacy of an ESP block compared to a TAP block in providing postoperative pain relief for patients undergoing laparoscopic cholecystectomy.

2 Methods

This systematic review and meta-analysis was registered in the International Prospective Register of Systematic Review with registration number CRD42024505635 and was performed according to the eligibility criteria of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations (27).

2.1 Search strategy

We systematically searched potentially relevant publications in the following electronic databases: MEDLINE, PubMed, Scopus, Embase, and Google Scholar from inception to 26 January 2024. We manually retrieved relevant studies using keywords and references from identified studies and limited our search to articles published in English; however, we did not limit the year of publication.

The search strategy consisted of the following terms in combination with Boolean operators: 'erector spinae plane block', 'transversus abdominis plane block', and 'laparoscopic cholecystectomy'. The search strategy for each database is attached as Supplementary File 1, and the retrieval process is illustrated in Figure 1.

2.2 Eligibility criteria

Studies that met the following criteria were considered eligible based on the PICOS criteria: (P) patients undergoing elective laparoscopic cholecystectomy (LC); (I) where the intervention group received ultrasound-guided ESP block; (C) the placebo or control group received TAP block; (O) postoperative pain scores, postoperative opioid consumption, first analgesia request time, and postoperative nausea and vomiting (PONV); and (S) randomized controlled trials.

The dosage, type, and volume of local anesthetics and the use of adjuvants in both groups did not affect the study's eligibility. We excluded trials comparing ESP block versus TAP block for surgical procedures other than LC. We also excluded retrospective studies, non-randomized controlled trials, and studies focused on outcomes other than our interests.

2.3 Selection criteria

Two reviewers (SE and TT) independently reviewed the titles and abstracts of the potential publications. The full texts of the initially identified articles that potentially met the eligibility criteria were re-reviewed before the final decision. A third reviewer (DZ) made the final decision in cases of disagreement.



Finally, the risk of bias was assessed for all included trials using the Review Manager (RevMan) software package, Version 5.4., Copenhagen.

This risk of bias tools included random sequence generation, concealment of treatment allocation, blinding throughout the study period, attrition, selective outcome reporting, and any other risk of bias, as presented in Figure 2.

2.4 Data extraction

Four reviewers (DZ, TT, TT, and SE) independently collected the relevant data from the included studies using a standardized data sheet. Extracted data included first author names, year of publication, study groups, local anesthetic dosage and types, adjuvants used, postoperative analgesia protocol, study outcomes, and other pertinent data from individual articles (Table 1).

We used standardized conversion equations to calculate the mean and standard deviation of the data presented as a median with an interquartile range or range (28). In the case of data displayed in a graphical format, we used plot digitization software (Plot Digitizer, 2.1, Free Software Foundation, Boston, MA, United States) to extract the numeric data.



2.5 Study outcomes

The primary outcome was the severity of pain scores at rest and during movement or coughing at 1, 2, 6, 12, and 24h after surgery. Pain scores reported as visual, verbal, or numeric rating scale scores were converted to a standardized 0 to 10 analog scale for the quantitative evaluations. The secondary outcomes were the postoperative total consumption of morphine equivalents, first analgesia request time, and PONV at 24h following LC. All types of opioids used for postoperative analgesia were converted to morphine equivalents (mg) using the British National Formulary standardized conversion tables (29).

For the primary outcomes of this review (i.e., the difference in pain score AUC from 1 to 24h), we conducted a sensitivity analysis as planned. This involved sequentially excluding data from trials that were (1) published in non-indexed journals, (2) available only as abstracts, and (3) non-randomized clinical trials.

2.6 Statistical analysis

One author (SE) entered data into Review Manager 5.4.1 (Cochrane Library, Oxford, United Kingdom), and another author (DZ) checked it for statistical analysis. Continuous data, such as the severity of pain scores at different time points, total tramadol consumption, and first analgesia request time at 24h after LC, were analyzed using mean difference (MD) or standard mean difference (SMD) with a 95% confidence interval (CI). On the other hand, dichotomous outcomes

TABLE 1 Patient's characteristics of the included trials.

| Author, year of publication | Patients characteristics | Sample size (ESPB/ TAPB) | Local anesthetics (type, dose) | Block location | Block timing | Postoperative analgesia protocol | Outcomes |
|-----------------------------------|---|-----------------------------------|--|---|--------------------|--|--|
| Altıparmak, et al. (21) | Patients aged 18– 70 years, ASA I-II for elective LC | 34/34 | 20 mL of 0.375% bupivacaine bilaterally for both blocks | ESPB at T7 Subcostal TAP block | Before incision | IV PCA of tramadol | Tramadol consumption, NRS pain score |
| Sahu et al. (19) | Patients aged 18– 70 years, ASA I-II for elective LC | 30/30 | 20 mL of 0.2% ropivacaine and 4 mg dexamethasone bilaterally for both blocks | ESPB at T7/T8 Subcostal TAP block | Awake states | iv Paracetamol iv Tramadol | Tramadol consumption, VAS pain score |
| Mounika et al. (20) | Patients aged 18– 70 years, ASA I-II for elective LC | 69/69 | 20 mL of 0.2% ropivacaine and 4 mg dexamethasone bilaterally for both blocks | ESPB at T7, Subcostal TAP block | Before incision | iv Paracetamol iv tramadol | Tramadol consumption, VAS pain score |
| Routray et al. (24) | Patients aged 18– 65 years, ASA I-II for elective LC | 35/35 | 20 mL of 0.375% bupivacaine bilaterally for both blocks | ESPB at T9, Subcostal TAP block | Before incision | iv Paracetamol | Paracetamol consumption, Analgesia request time, NRS pain score |
| Engineer et al. (18) | Patients aged 18– 75 years, ASA I-III for elective LC | 30/30 | 20 mL (10 mL of 0.375% bupivacaine and 10 mL of 1.5% lignoadrenaline) bilaterally for both blocks | ESPB at T9, Subcostal TAP block | Before incision | iv tramadol, im diclofenac | First analgesic request time, NRS pain score |
| Tulgar et al. (23) | Patients aged 18– 65 years, ASA I-II for elective LC | 20/20 | 20 mL (10 mL of bupivacaine 0.5%, 5 mL of lidocaine 2% and 5 mL normal saline) bilaterally for both blocks | ESPB at T9, Subcostal TAP block | Before incision | iv Paracetamol iv PCA of Tramadol, iv Fentanyl | Tramadol consumption, NRS pain score |
| Ozdemir et al. (22) | Patients aged 18– 64 years, ASA I-III for elective LC | 32/32 | 10 mL of 0.25% bupivacaine and 10 mL of 2% prilocaine bilaterally for both blocks | ESPB at T7, Subcostal TAP block | Awake states | iv Paracetamol iv Meperidine, iv PCA of fentanyl | NRS pain score Time to first analgesic request and fentanyl consumption. |
| Ibrahim (25) | Patients aged 20– 60 years, ASA I-II for elective LC | 21/21 | 20 mL of 0.25% bupivacaine bilaterally for both blocks | ESPB at T8, Subcostal TAP block | Before incision | iv Paracetamol iv PCA of Morphine | Morphine consumption, VAS score and first analgesic dose |

were analyzed using relative risk (RR) with a 95% confidence interval (CI). We performed a statistical heterogeneity analysis using Higgins's I2 test. We used a random-effects model for the meta-analysis,

regardless of the I2 results. A *p*-value of <0.05 was considered statistically significant for all tests. Whenever necessary, we conducted a sensitivity analysis to identify the sources of heterogeneity.

3 Results

3.1 Search results

We identified a total of 187 studies through electronic databases and manual searches. After removing duplicates, we screened the title and abstract of each article. Of these, 126 articles were excluded from the meta-analysis because they did not meet the inclusion criteria during title and abstract screening. Finally, 8 randomized controlled trials published between 2019 and 2023 comprising 542 patients met the inclusion criteria (Figure 1).

3.2 Risk of bias assessment

All the included studies were RCTs. We described trial characteristics and relevant details about the included articles (Table 1). We used RevMan software's risk of bias tool for systematic reviews of interventions to evaluate the included trials (Figure 2). Clear eligibility criteria for each included trial and a detailed randomization step were summarized. Patients were blinded to the type of block they received, except in two trials, in which, ESP and TAP blocks were performed in an awake state (19, 21). In addition, there was an unknown risk of blinding of outcome assessment (18, 20, 22) and allocation concealment (20).

3.3 Study characteristics

The sample sizes in the included RCTs ranged from 40 to 138. All studies compared the efficacy of ESPB and TAPB for postoperative analgesia following LC. The intervention groups received ESPB, whereas the control groups received TAPB. All the included trials used standardized anesthesia induction protocols. Propofol was used for general anesthesia induction along with fentanyl (18, 21–25) and nalbuphine (19, 20). Three studies (21–23) used opioids with inhalational agents as a part of anesthesia maintenance, and the remainder used inhalational agents alone.

All patients, except in two trials (19, 22), received ESPB or TAPB under general anesthesia before the surgical incision. Dosages, types, drug mixtures, and adjuvants used with local anesthetics varied between studies; however, the same dose and type of drugs were administered for both blocks in all studies. All trials used a postoperative analgesia protocol for pain management; however, four studies (21–23, 25) used patient-controlled analgesia (PCA).

3.4 Outcomes in the meta-analysis

3.4.1 Postoperative pain scores at rest and on movement during 24 h postoperatively

The primary outcome was the pain score at different time points (1, 2, 6, 12, and 24h) postoperatively at rest and on active movement following LC.

3.4.1.1 Postoperative pain scores at rest

In seven trials comprising patients between 372 and 478, the authors reported pain scores at different time points following

LC. There was significant heterogeneity across the specified time points (I2 = 55%, p < 0.001); therefore, we used a random-effects model. The pooled results demonstrated that there was a statistically significant difference in favor of the ESPB group over the TAPB group in terms of postoperative pain score at 1 (MD = -0.65, 95% CI: -0.90 to -0.41; p < 0.001; I2 = 72%), 2 (MD = -0.49, 95% CI: -0.59 to -0.39; p < 0.001; I2 = 46%), 6 (MD = -0.64, 95% CI: -0.84 to -0.44; p < 0.001; I2 = 58%), 12 (MD = -0.52, 95% CI: -0.72 to -0.33; p < 0.001; I2 = 63%), and 24 h (MD = -0.48, 95% CI: -0.54 to -0.43; p < 0.001; I2 = 0%), as shown in Figure 3.

3.4.1.2 Postoperative pain scores on movement

Patients who underwent LC reported their postoperative pain scores at 1, 2, 6, 12, and 24 h after movement in five trials involving 128 to 280 patients. Significant heterogeneity was found between the studies at the predetermined time points (I2 = 71%, p < 0.001); therefore, a random-effects model was computed. The results of the meta-analysis revealed that the ESPB had significantly lower postoperative pain scores on movement at 2 (MD = -0.68, 95% CI: -0.81 to -0.54; p < 0.001; I2 = 37%), 12 (MD = -0.49, 95% CI: -0.60 to -0.38; p < 0.001; I2 = 0%), and 24 h (MD = -0.40, 95% CI: -0.48 to -0.33; p < 0.001; I2 = 0%) than the TAPB groups, as displayed in Figure 4. However, there were no significant differences between these two blocks at 1 (MD = -0.53, 95% CI: -1.22 to 0.15; p = 0.13; I2 = 88%) and 6 h (MD = -0.46, 95% CI: -0.92 to -0.00; p = 0.05; I2 = 81%).

3.4.2 Intravenous morphine equivalent consumption at 24h postoperatively

Seven RCTs comprising 478 participants reported opioid consumption at 24 h postoperatively following LC. Four trials (18, 20, 21, 23) included IV tramadol, and others used fentanyl (22) and morphine (24, 25) to control postoperative pain. All opioids were converted to morphine equivalents (mg) to simplify the data analysis. Given the significant heterogeneity (Chi² = 116.44, df = 6, I2 = 95%, p < 0.001), a random-effects model was used. The results of the meta-analysis indicated that the ESPB significantly lowered morphine equivalent consumption at 24 h postoperatively (MD = -3.51, 95% CI: -5.31 to -1.71; p < 0.001) than the TAPB group (Figure 5).

3.4.3 First analgesia request time in minutes

Four studies (18, 22, 24, 25) with 238 patients reported the first analgesia request time after LC. There was significant heterogeneity (Chi2 = 44.56, df = 3, I2 = 93%, p < 0.001); therefore, a random-effects model was used. The pooled results showed a significant difference between the two groups in the time to request first analgesia (MD = 66.86, 93% CI: 24.85 to 108.86; p = 0.002), as shown in Figure 6.

3.4.4 Incidence of postoperative nausea and vomiting (PONV)

Five trials (19–21, 24, 25) provided information about the incidence of PONV at 24h following LC. There was no significant heterogeneity (Chi²=7.13, df=4, I²=44%, p=0.13); however, a random-effects model was used. The pooled results revealed that there was no significant difference between the groups in the incidence of PONV (RR 0.70, 95% CI: 0.29 to 1.70, p=0.43).

| Study of Subgroup | | ESPB | Total | | APB | Total | Moight | Mean Difference | Mean Difference |
|--|--|--|--|---|---|--|--|--|--------------------|
| Study or Subgroup 4.1.1 At 1 hour | Mean | 50 | Total | Mean | 50 | Total | weight | IV, Random, 95% CI | IV, Random, 95% CI |
| | 2 | 0.40 | 24 | 2.0 | 0.0 | 24 | 4.000 | 0 00 / 4 00 0 741 | |
| B. Altiparmak, et al., 2019 Engineer et al., 2022 | | 0.48 0.73 | 34 30 | 2.9 | 0.3 0.73 | 34 30 | 4.9% 2.2% | -0.90 [-1.09, -0.71] -0.70 [-1.07, -0.33] | |
| Mounika et al., 2023 | | 0.25 | 69 | 1.5 | 0.73 | 50 69 | 6.4% | -0.50 [-0.63, -0.37] | |
| Routray et al., 2020 | 1.98 | 1.4 | 35 | 2.85 | 1.1 | 35 | 1.0% | -0.87 [-1.46, -0.28] | <u> </u> |
| Tulgar, et al., 2019 | | 1.03 | 20 | 1.05 | | 20 | 1.1% | | |
| Subtotal (95% CI) | 0.00 | 1.03 | 188 | 1.05 | 0.70 | 188 | 15.5% | -0.20 [-0.76, 0.36] -0.65 [-0.90, -0.41] | |
| Heterogeneity: Tau ² = 0.05; · | Chi≩ – 1 | 1 50 0 | | - 0.00 | s) · I Z – | | 10.070 | -0.00[-0.00,-0.41] | |
| Test for overall effect: Z = 5.1 | | | | - 0.000 | o), r = | 7270 | | | |
| 4.1.2 At 2 hour | | | | | | | | | |
| B. Altıparmak, et al., 2019 | 2.5 | 0.24 | 34 | 2.89 | 0.24 | 34 | 6.9% | -0.39 [-0.50, -0.28] | _ — |
| H. Ozdemir et al., 2021 | 1.4 | 0.9 | 32 | 2.4 | 1.1 | 32 | 1.4% | -1.00 [-1.49, -0.51] | ← |
| lbrahim M., 2020 | | 0.25 | 21 | | 0.25 | 21 | 5.9% | -0.50 [-0.65, -0.35] | (|
| Lingaraj S et al., 2021 | 1.6 | 1.1 | 30 | 2.27 | 1.1 | 30 | 1.1% | -0.67 [-1.23, -0.11] | ← |
| Mounika et al., 2023 | | 0.25 | 69 | | 0.25 | 69 | 7.8% | -0.50 [-0.58, -0.42] | — |
| Subtotal (95% CI) | | 0.20 | 186 | 0.0 | 0.20 | 186 | 23.0% | -0.49 [-0.59, -0.39] | • |
| Heterogeneity: Tau ² = 0.01; | $Chi^2 = 7$ | 41. df | = 4 (P = | = 0.12): | $ ^{2} = 48$ | i% | | | • |
| Test for overall effect: Z = 9.4 | | | | 0.12/1 | | | | | |
| 4.1.3 At 6 hour | | | | | | | | | |
| Engineer et al., 2022 | 2.5 | 0.73 | 30 | 3.25 | 0.98 | 30 | 1.7% | -0.75 [-1.19, -0.31] | ←───── |
| H. Ozdemir et al., 2021 | 0.3 | | 32 | 0.9 | 0.7 | 32 | 2.9% | -0.60 [-0.90, -0.30] | |
| Ibrahim M., 2020 | | 0.25 | 21 | 3.5 | 0.5 | 21 | 3.9% | -0.60 [-0.84, -0.36] | |
| Lingaraj S et al., 2021 | 0.9 | 0.6 | 30 | 2.33 | 1.3 | 30 | 1.3% | -1.43 [-1.94, -0.92] | <u>←</u> |
| Mounika et al., 2023 | | 0.25 | 69 | 3.5 | 0.5 | 69 | 6.4% | -0.50 [-0.63, -0.37] | _ — |
| Routray et al., 2020 | | 1.95 | 35 | | 1.12 | 35 | 0.6% | -0.40 [-1.14, 0.34] | |
| Tulgar, et al., 2019 | | 1.34 | 20 | 1.75 | | 20 | 0.7% | -0.15 [-0.87, 0.57] | |
| Subtotal (95% CI) | | | | | | 237 | | | |
| and the second second second | | | 237 | | | 231 | 17.5% | -0.64 [-0.84, -0.44] | • |
| Heterogeneity: Tau² = 0.03; Test for overall effect: Z = 6.2 | | | if = 6 (F | 9 = 0.03) | ; I ² = 6 | | 17.5% | -0.04 [-0.84, -0.44] | - |
| Heterogeneity: Tau ² = 0.03; | | | if = 6 (F | 9 = 0.03) | ; I ² = € | | 17.5% | -0.04 [-0.84, -0.44] | - |
| Heterogeneity: Tau ² = 0.03; Test for overall effect: Z = 6.2 4.1.4 At 12 hour | 22 (P ≺ I | 0.0000 | lf = 6 (F 1) | | | 8% | | | - |
| Heterogeneity: Tau² = 0.03; Test for overall effect: Z = 6.2 4.1.4 At 12 hour B. Altıparmak, et al., 2019 | 22 (P < 1 2.8 | 0.0000 | if = 6 (F 1) 34 | 3 | 0.48 | ;8% 34 | 5.1% | -0.20 [-0.38, -0.02] | |
| Heterogeneity: Tau² = 0.03; Test for overall effect: Z = 6.2 4.1.4 At 12 hour B. Altıparmak, et al., 2019 Engineer et al., 2022 | 22 (P < 1 2.8 2.9 | 0.0000 0.24 0.73 | f = 6 (F 1) 34 30 | 3 3.64 | 0.48 0.73 | i8% 34 30 | 5.1% 2.2% | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] | |
| Heterogeneity: Tau² = 0.03; Test for overall effect: Z = 6.2 4.1.4 At 12 hour B. Altıparmak, et al., 2019 Engineer et al., 2022 Ibrahim M., 2020 | 22 (P < 1 2.8 2.9 2.6 | 0.0000 0.24 0.73 0.5 | 4f = 6 (F 1) 34 30 21 | 3 3.64 3.2 | 0.48 0.73 0.25 | 34 30 21 | 5.1% 2.2% 3.9% | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] -0.60 [-0.84, -0.36] | |
| Heterogeneity: Tau ² = 0.03; Test for overall effect: Z = 6.2 4.1.4 At 12 hour B. Altıparmak, et al., 2019 Engineer et al., 2022 Ibrahim M., 2020 Lingaraj S et al., 2021 | 22 (P < 1 2.8 2.9 2.6 0.83 | 0.0000 0.24 0.73 0.5 1.5 | f = 6 (F 1) 34 30 21 30 | 3 3.64 3.2 2.23 | 0.48 0.73 0.25 2.1 | 34 30 21 30 | 5.1% 2.2% 3.9% 0.4% | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] -0.60 [-0.84, -0.36] -1.40 [-2.32, -0.48] | |
| Heterogeneity: Tau ² = 0.03; Test for overall effect: Z = 6.2 4.1.4 At 12 hour B. Altıparmak, et al., 2019 Engineer et al., 2022 Ibirahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 | 22 (P < 1 2.8 2.9 2.6 0.83 2.5 | 0.0000 0.24 0.73 0.5 1.5 0.25 | ff = 6 (F 1) 34 30 21 30 69 | 3 3.64 3.2 2.23 3 | 0.48 0.73 0.25 2.1 0.5 | 34 30 21 30 69 | 5.1% 2.2% 3.9% 0.4% 6.4% | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] -0.60 [-0.84, -0.36] -1.40 [-2.32, -0.48] -0.50 [-0.63, -0.37] | |
| Heterogeneity: Tau ² = 0.03; Test for overall effect: Z = 6.2 4.1.4 At 12 hour B. Altıparmak, et al., 2019 Engineer et al., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 | 22 (P < 1 2.8 2.9 2.6 0.83 2.5 2.1 | 0.0000 0.24 0.73 0.5 1.5 0.25 1.7 | lf = 6 (F 1) 34 30 21 30 69 35 | 3 3.64 3.2 2.23 3 2.8 | 0.48 0.73 0.25 2.1 0.5 1.89 | 34 30 21 30 69 35 | 5.1% 2.2% 3.9% 0.4% 6.4% 0.5% | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] -0.60 [-0.84, -0.36] -1.40 [-2.32, -0.48] -0.50 [-0.63, -0.37] -0.70 [-1.54, 0.14] | |
| Heterogeneity: Tau ² = 0.03; Test for overall effect: Z = 6.2 4.1.4 At 12 hour B. Altiparmak, et al., 2019 Engineer et al., 2022 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2019 | 22 (P < 1 2.8 2.9 2.6 0.83 2.5 2.1 | 0.0000 0.24 0.73 0.5 1.5 0.25 | lf = 6 (F 1) 34 30 21 30 69 35 20 | 3 3.64 3.2 2.23 3 2.8 | 0.48 0.73 0.25 2.1 0.5 | 34 30 21 30 69 35 20 | 5.1% 2.2% 3.9% 0.4% 6.4% 0.5% 1.0% | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] -0.60 [-0.84, -0.36] -1.40 [-2.32, -0.48] -0.50 [-0.63, -0.37] -0.70 [-1.54, 0.14] -0.45 [-1.03, 0.13] | |
| Heterogeneity: Tau ² = 0.03; Test for overall effect: Z = 6.2 4.1.4 At 12 hour B. Altiparmak, et al., 2019 Engineer et al., 2022 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 Tulgar, et al., 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.03; | 22 (P < 1 2.8 2.9 2.6 0.83 2.5 2.1 1.75 Chi ² = 1 | 0.0000 0.24 0.73 0.5 1.5 0.25 1.7 0.99 6.15, 0 | ff = 6 (F 1) 34 30 21 30 69 35 20 239 ff = 6 (F | 3 3.64 3.2 2.23 3 2.8 2.2 | 0.48 0.73 0.25 2.1 0.5 1.89 0.89 | 34 30 21 30 69 35 20 239 | 5.1% 2.2% 3.9% 0.4% 6.4% 0.5% | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] -0.60 [-0.84, -0.36] -1.40 [-2.32, -0.48] -0.50 [-0.63, -0.37] -0.70 [-1.54, 0.14] | |
| Heterogeneity: Tau ² = 0.03; Test for overall effect: Z = 6.2 4.1.4 At 12 hour B. Altiparmak, et al., 2019 Engineer et al., 2022 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 Tulgar, et al., 2019 Subtotal (95% CI) | 22 (P < 1 2.8 2.9 2.6 0.83 2.5 2.1 1.75 Chi ² = 1 | 0.0000 0.24 0.73 0.5 1.5 0.25 1.7 0.99 6.15, 0 | ff = 6 (F 1) 34 30 21 30 69 35 20 239 ff = 6 (F | 3 3.64 3.2 2.23 3 2.8 2.2 | 0.48 0.73 0.25 2.1 0.5 1.89 0.89 | 34 30 21 30 69 35 20 239 | 5.1% 2.2% 3.9% 0.4% 6.4% 0.5% 1.0% | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] -0.60 [-0.84, -0.36] -1.40 [-2.32, -0.48] -0.50 [-0.63, -0.37] -0.70 [-1.54, 0.14] -0.45 [-1.03, 0.13] | |
| Heterogeneity: Tau ² = 0.03; Test for overall effect: Z = 6.2 4.1.4 At 12 hour B. Altiparmak, et al., 2019 Engineer et al., 2022 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 Tulgar, et al., 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.03; | 22 (P < 1 2.8 2.9 2.6 0.83 2.5 2.1 1.75 Chi ² = 1 | 0.0000 0.24 0.73 0.5 1.5 0.25 1.7 0.99 6.15, 0 | ff = 6 (F 1) 34 30 21 30 69 35 20 239 ff = 6 (F | 3 3.64 3.2 2.23 3 2.8 2.2 | 0.48 0.73 0.25 2.1 0.5 1.89 0.89 | 34 30 21 30 69 35 20 239 | 5.1% 2.2% 3.9% 0.4% 6.4% 0.5% 1.0% | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] -0.60 [-0.84, -0.36] -1.40 [-2.32, -0.48] -0.50 [-0.63, -0.37] -0.70 [-1.54, 0.14] -0.45 [-1.03, 0.13] | |
| Heterogeneity: Tau ² = 0.03; Test for overall effect: Z = 6.2 4.1.4 At 12 hour B. Altıparmak, et al., 2019 Engineer et al., 2022 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 Tulgar, et al., 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.03; Test for overall effect: Z = 5.3 | 22 (P < 1 2.8 2.9 2.6 0.83 2.5 2.1 1.75 Chi ² = 1 30 (P < 1 | 0.0000 0.24 0.73 0.5 1.5 0.25 1.7 0.99 6.15, 0 | ff = 6 (F 1) 34 30 21 30 69 35 20 239 ff = 6 (F | 3 3.64 3.2 2.23 3 2.8 2.2 2.2 2.2 | 0.48 0.73 0.25 2.1 0.5 1.89 0.89 | 34 30 21 30 69 35 20 239 | 5.1% 2.2% 3.9% 0.4% 6.4% 0.5% 1.0% | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] -0.60 [-0.84, -0.36] -1.40 [-2.32, -0.48] -0.50 [-0.63, -0.37] -0.70 [-1.54, 0.14] -0.45 [-1.03, 0.13] | |
| Heterogeneity: Tau ² = 0.03; Test for overall effect: Z = 6.2 4.1.4 At 12 hour B. Altıparmak, et al., 2019 Engineer et al., 2022 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 Tulgar, et al., 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.03; Test for overall effect: Z = 5.3 4.1.5 At 24 hour | 22 (P < 1 2.8 2.9 2.6 0.83 2.5 2.1 1.75 Chi ² = 1 30 (P < 1 | 0.0000 0.24 0.73 0.5 1.5 0.25 1.7 0.99 6.15, 0 0.0000 | ff = 6 (F 1) 34 30 21 30 69 35 20 239 ff = 6 (F 1) | 3 3.64 3.2 2.23 3 2.8 2.2 2.2 2.2 | 0.48 0.73 0.25 2.1 0.5 1.89 0.89 ; I ² = 6 | 34 30 21 30 69 35 20 239 33% | 5.1% 2.2% 3.9% 0.4% 6.4% 0.5% 1.0% 19.5 % | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] -0.60 [-0.84, -0.36] -1.40 [-2.32, -0.48] -0.50 [-0.63, -0.37] -0.70 [-1.54, 0.14] -0.45 [-1.03, 0.13] -0.52 [-0.72, -0.33] | |
| Heterogeneity: Tau ² = 0.03; Test for overall effect: Z = 6.2 4.1.4 At 12 hour B. Altiparmak, et al., 2019 Engineer et al., 2020 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 Tulgar, et al., 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.03; Test for overall effect: Z = 5.3 4.1.5 At 24 hour B. Altiparmak, et al., 2019 Ibrahim M., 2020 | 22 (P < 1 2.8 2.9 2.6 0.83 2.5 2.1 1.75 Chi ^z = 1 30 (P < 1 1.03 | 0.0000 0.24 0.73 0.5 1.5 0.25 1.7 0.99 6.15, 0 0.0000 0.06 0.5 | ff = 6 (F 1) 34 30 21 30 69 35 20 239 ff = 6 (F 1) 34 | 3 3.64 3.2 2.23 3 2.8 2.2 ? = 0.01) 1.5 2.6 | 0.48 0.73 0.25 2.1 0.5 1.89 0.89 c; I ² = 6 | 34 30 21 30 69 35 20 239 33% | 5.1% 2.2% 3.9% 0.4% 6.4% 0.5% 1.0% 19.5% | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] -0.60 [-0.84, -0.36] -1.40 [-2.32, -0.48] -0.50 [-0.63, -0.37] -0.70 [-1.54, 0.14] -0.45 [-1.03, 0.13] -0.52 [-0.72, -0.33] | |
| Heterogeneity: Tau ² = 0.03; Test for overall effect: $Z = 6.2$ 4.1.4 At 12 hour B. Altiparmak, et al., 2019 Engineer et al., 2020 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 Tulgar, et al., 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.03; Test for overall effect: $Z = 5.3$ 4.1.5 At 24 hour B. Altiparmak, et al., 2019 Ibrahim M., 2020 Lingaraj S et al., 2021 | 22 (P < 1 2.8 2.9 2.6 0.83 2.5 2.1 1.75 Chi ² = 1 30 (P < 1 1.03 2.1 0.1 | 0.0000 0.24 0.73 0.5 1.5 0.25 1.7 0.99 6.15, 0 0.0000 0.0000 | ff = 6 (F 1) 34 30 21 30 69 35 20 239 ff = 6 (F 1) 34 21 | 3 3.64 3.2 2.23 3 2.8 2.2 ? = 0.01) 1.5 2.6 0.7 | 0.48 0.73 0.25 2.1 0.5 1.89 0.89 c, I ² = 6 0.24 0.24 | 34 30 21 30 69 35 20 239 33% 34 21 | 5.1% 2.2% 3.9% 6.4% 0.5% 1.0% 1 9.5% 7.8% 2.9% | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] -0.60 [-0.84, -0.36] -1.40 [-2.32, -0.48] -0.50 [-0.63, -0.37] -0.70 [-1.54, 0.14] -0.45 [-1.03, 0.13] -0.52 [-0.72, -0.33] -0.52 [-0.72, -0.33] -0.50 [-0.80, -0.20] -0.60 [-0.95, -0.25] | |
| Heterogeneity: Tau ² = 0.03; Test for overall effect: Z = 6.2 4.1.4 At 12 hour B. Altıparmak, et al., 2019 Engineer et al., 2022 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 Tulgar, et al., 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.03; Test for overall effect: Z = 5.3 4.1.5 At 24 hour B. Altıparmak, et al., 2019 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 | 22 (P < 1 2.8 2.9 2.6 0.83 2.5 2.1 1.75 Chi ² = 1 30 (P < 1 30 (P < 1 1.03 2.1 0.1 2.5 | 0.24 0.23 0.5 1.5 0.25 1.7 0.99 6.15, 0 0.0000 0.0000 0.0000 0.06 0.5 0.69 0.25 | ff = 6 (F 1) 34 30 21 30 239 35 20 239 ff = 6 (F 1) 34 21 30 69 | 3 3.64 2.23 3 2.8 2.2 ? = 0.01) 1.5 2.6 0.7 3 | 0.48 0.73 0.25 2.1 0.5 1.89 0.89 ; ² = £ 0.24 0.5 0.69 0.25 | 34 30 21 30 69 35 20 239 33% 34 21 30 69 | 5.1% 2.2% 3.9% 0.4% 6.4% 1.0% 19.5% 7.8% 2.9% 2.4% 7.8% | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] -0.60 [-0.84, -0.36] -1.40 [-2.32, -0.48] -0.50 [-0.63, -0.37] -0.70 [-1.54, 0.14] -0.45 [-1.03, 0.13] -0.52 [-0.72, -0.33] -0.52 [-0.72, -0.33] -0.50 [-0.80, -0.20] -0.60 [-0.95, -0.25] -0.50 [-0.58, -0.42] | |
| Heterogeneity: $Tau^2 = 0.03$; Test for overall effect: $Z = 6.2$ 4.1.4 At 12 hour B. Altıparmak, et al., 2019 Engineer et al., 2022 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 Subtotal (95% CI) Heterogeneity: $Tau^2 = 0.03$; Test for overall effect: $Z = 5.3$ 4.1.5 At 24 hour B. Altıparmak, et al., 2019 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 | 22 (P < 1 2.8 2.9 2.6 0.83 2.5 2.1 1.75 Chi ² = 1 30 (P < 1 1.03 2.1 0.1 0.1 2.5 3.15 | 0.24 0.73 0.5 1.5 0.25 1.7 0.99 6.15,0 0.0000 0.000 0.000 0.5 0.69 0.25 0.81 | if = 6 (F (F) 1) 34 300 21 300 239 35 200 239 if = 6 (F 1) 34 21 30 69 35 20 239 35 20 239 35 20 239 36 36 36 35 20 239 36 36 36 36 36 36 35 20 239 35 20 239 35 20 239 35 20 239 35 20 239 35 20 239 35 20 239 35 20 239 35 20 239 35 20 239 35 20 239 35 20 239 35 20 239 35 20 239 35 20 239 35 20 239 35 20 20 20 20 20 20 20 20 20 20 | 3 3.64 3.2 2.23 3 2.8 2.2 ? = 0.01) 1.5 2.6 0.7 3.69 | 0.48 0.73 0.25 2.1 0.5 1.89 0.89 ; I ² = 6 0.24 0.5 0.69 0.25 0.9 | 34 30 21 30 9 9 35 20 239 33% 34 21 30 69 35 | 5.1% 2.2% 3.9% 0.4% 6.4% 1.0% 19.5% 7.8% 2.4% 2.4% 7.8% 1.9% | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] -0.60 [-0.84, -0.36] -1.40 [-2.32, -0.48] -0.50 [-0.63, -0.37] -0.70 [-1.54, 0.14] -0.45 [-1.03, 0.13] -0.52 [-0.72, -0.33] -0.50 [-0.72, -0.33] -0.50 [-0.80, -0.20] -0.60 [-0.95, -0.25] -0.50 [-0.58, -0.42] -0.54 [-0.94, -0.14] | |
| Heterogeneity: $Tau^2 = 0.03$; Test for overall effect: $Z = 6.2$ 4.1.4 At 12 hour B. Altıparmak, et al., 2019 Engineer et al., 2022 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 Tulgar, et al., 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.03; Test for overall effect: $Z = 5.3$ 4.1.5 At 24 hour B. Altıparmak, et al., 2019 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 Tulgar, et al., 2020 | 22 (P < 1 2.8 2.9 2.6 0.83 2.5 2.1 1.75 Chi ² = 1 30 (P < 1 1.03 2.1 0.1 0.1 2.5 3.15 | 0.24 0.23 0.5 1.5 0.25 1.7 0.99 6.15, 0 0.0000 0.0000 0.0000 0.06 0.5 0.69 0.25 | ff = 6 (F 1) 34 30 21 30 239 35 20 239 ff = 6 (F 1) 34 21 30 69 | 3 3.64 2.23 3 2.8 2.2 ? = 0.01) 1.5 2.6 0.7 3 | 0.48 0.73 0.25 2.1 0.5 1.89 0.89 ; I ² = 6 0.24 0.5 0.69 0.25 0.9 | 34 30 21 30 69 35 20 239 33% 34 21 30 69 | 5.1% 2.2% 3.9% 0.4% 6.4% 1.0% 19.5% 7.8% 2.9% 2.4% 7.8% | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] -0.60 [-0.84, -0.36] -1.40 [-2.32, -0.48] -0.50 [-0.63, -0.37] -0.70 [-1.54, 0.14] -0.45 [-1.03, 0.13] -0.52 [-0.72, -0.33] -0.52 [-0.72, -0.33] -0.50 [-0.80, -0.20] -0.60 [-0.95, -0.25] -0.50 [-0.58, -0.42] -0.54 [-0.94, -0.14] -0.20 [-0.62, 0.22] | |
| Heterogeneity: $Tau^2 = 0.03$; Test for overall effect: $Z = 6.2$ 4.1.4 At 12 hour B. Altıparmak, et al., 2019 Engineer et al., 2022 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 Tulgar, et al., 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.03; Test for overall effect: $Z = 5.3$ 4.1.5 At 24 hour B. Altıparmak, et al., 2019 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 Tulgar, et al., 2020 Subtotal (95% CI) Heterogeneity: Tau ² = 0.00; | 22 (P < 1 2.8 2.9 2.6 0.83 2.5 2.1 1.75 Chi ² = 1 30 (P < 1 1.03 2.1 0.1 2.5 3.15 1.65 Chi ² = 2 | 0.24 0.73 0.5 1.5 0.25 1.7 0.99 6.15, (0.0000 0.06 0.5 0.69 0.25 0.81 0.69 | if = 6 (F (F) 1) 34 30 239 35 20 239 35 20 239 1) 34 21 30 69 35 20 239 9 35 20 239 9 35 20 239 9 35 20 239 9 35 20 239 9 35 20 239 9 35 20 239 9 35 20 239 9 35 20 239 9 35 20 239 9 35 20 239 9 35 20 239 9 35 20 239 9 35 20 239 9 35 20 239 9 35 20 239 9 35 20 239 9 35 20 239 9 35 20 20 239 9 35 20 20 20 20 20 20 20 20 20 20 | 3 3.64 3.2 2.23 3 2.8 2.2 9 = 0.01) 1.5 2.6 0.7 3 3.69 1.85 | 0.48 0.73 0.25 2.1 0.5 1.89 0.89 ; ² = 0 0.24 0.5 0.69 0.25 0.9 0.67 | 34 300 21 30 69 35 20 239 35 20 239 33% 34 21 30 69 35 20 209 | 5.1% 2.2% 3.9% 0.4% 0.5% 1.0% 19.5% 7.8% 2.9% 2.4% 7.8% 1.9% 1.8% | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] -0.60 [-0.84, -0.36] -1.40 [-2.32, -0.48] -0.50 [-0.63, -0.37] -0.70 [-1.54, 0.14] -0.45 [-1.03, 0.13] -0.52 [-0.72, -0.33] -0.50 [-0.72, -0.33] -0.50 [-0.80, -0.20] -0.60 [-0.95, -0.25] -0.50 [-0.58, -0.42] -0.54 [-0.94, -0.14] | |
| Heterogeneity: $Tau^2 = 0.03$; Test for overall effect: $Z = 6.2$ 4.1.4 At 12 hour B. Altıparmak, et al., 2019 Engineer et al., 2022 Ibrahim M., 2020 Lingaraj S et al., 2023 Routray et al., 2020 Tulgar, et al., 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.03; Test for overall effect: $Z = 5.3$ 4.1.5 At 24 hour B. Altıparmak, et al., 2019 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 Tulgar, et al., | 22 (P < 1 2.8 2.9 2.6 0.83 2.5 2.1 1.75 Chi ² = 1 30 (P < 1 1.03 2.1 0.1 2.5 3.15 1.65 Chi ² = 2 | 0.24 0.73 0.5 1.5 0.25 1.7 0.99 6.15, (0.0000 0.06 0.5 0.69 0.25 0.81 0.69 | if = 6 (F 1) 34 30 21 30 69 35 20 23 20 23 if = 6 (F 1) 34 21 30 69 35 20 20 9 35 20 20 9 35 20 9 35 20 9 35 20 20 9 35 20 20 9 35 20 20 20 20 21 30 35 20 20 21 30 35 20 20 20 21 30 21 20 20 20 20 20 20 20 20 20 20 20 20 20 | 3 3.64 3.2 2.23 3 2.8 2.2 9 = 0.01) 1.5 2.6 0.7 3 3.69 1.85 | 0.48 0.73 0.25 2.1 0.5 1.89 0.89 ; ² = 0 0.24 0.5 0.69 0.25 0.9 0.67 | 34 30 21 30 69 35 20 239 35 35 35 35 35 20 209 35 20 209 % | 5.1% 2.2% 3.9% 0.4% 6.4% 1.0% 19.5% 7.8% 2.9% 2.4% 7.8% 1.9% 1.8% 24.4% | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] -0.60 [-0.84, -0.36] -1.40 [-2.32, -0.48] -0.50 [-0.63, -0.37] -0.70 [-1.54, 0.14] -0.45 [-1.03, 0.13] -0.52 [-0.72, -0.33] -0.50 [-0.72, -0.33] -0.50 [-0.80, -0.20] -0.60 [-0.95, -0.25] -0.50 [-0.58, -0.42] -0.54 [-0.94, -0.14] -0.20 [-0.62, 0.22] -0.48 [-0.54, -0.43] | |
| Heterogeneity: $Tau^2 = 0.03$; Test for overall effect: $Z = 6.2$ 4.1.4 At 12 hour B. Altıparmak, et al., 2019 Engineer et al., 2022 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 Tulgar, et al., 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.03; Test for overall effect: $Z = 5.3$ 4.1.5 At 24 hour B. Altıparmak, et al., 2019 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 Tulgar, et al., 2021 Mourika et al., 2023 Routray et al., 2020 Tulgar, et al., 2020 Tulgar, et al., 2020 Tulgar, et al., 2020 Tulgar, et al., 2021 Mourika et al., 2023 Routray et al., 2020 Tulgar, et al., | 22 (P < 1 2.8 2.9 2.6 0.83 2.5 2.1 1.75 Chi ² = 1 30 (P < 1 1.03 2.1 0.1 2.5 3.15 1.65 Chi ² = 2 0.97 (P < | 0.244 0.73 0.5 1.5 0.25 1.7 0.99 6.15, (0.0000 0.000 0.5 0.69 0.25 0.69 0.25 0.69 0.25 0.69 | if = 6 (F (F) 1) 34 30 21 30 69 35 20 23 9 35 20 23 9 35 20 23 9 35 20 20 9 35 20 20 9 35 20 20 20 20 20 20 20 20 20 20 | 3 3.64 3.2 2.23 3 2.8 2.2 ? = 0.01) 1.5 2.6 0.7 3.69 1.85 = 0.78); | 0.48 0.73 0.25 2.1 0.5 1.89 0.89 0.24 0.5 0.69 0.25 0.69 0.25 0.9 0.67 | 34 30 21 30 69 35 20 239 35 20 239 35 20 3% 34 21 30 69 5 20 209 6 5 | 5.1% 2.2% 3.9% 0.4% 6.4% 0.5% 1.0% 19.5% 7.8% 2.4% 7.8% 1.9% 1.8% 24.4% | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] -0.60 [-0.84, -0.36] -1.40 [-2.32, -0.48] -0.50 [-0.63, -0.37] -0.70 [-1.54, 0.14] -0.45 [-1.03, 0.13] -0.52 [-0.72, -0.33] -0.52 [-0.72, -0.33] -0.50 [-0.80, -0.20] -0.60 [-0.95, -0.25] -0.50 [-0.58, -0.42] -0.54 [-0.94, -0.14] -0.20 [-0.62, 0.22] | |
| Heterogeneity: $Tau^2 = 0.03$; Test for overall effect: $Z = 6.2$ 4.1.4 At 12 hour B. Altıparmak, et al., 2019 Engineer et al., 2022 Ibrahim M., 2020 Lingaraj S et al., 2023 Routray et al., 2020 Tulgar, et al., 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.03; Test for overall effect: $Z = 5.3$ 4.1.5 At 24 hour B. Altıparmak, et al., 2019 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 Tulgar, et al., | 22 (P < 1 2.8 2.9 2.6 0.83 2.5 2.1 1.75 Chi ² = 1 30 (P < 1 1.03 2.1 0.1 2.5 3.15 1.65 Chi ² = 2 5.97 (P < Chi ² = 6 5.95 (P < | 0.24 0.73 0.5 1.5 0.25 1.7 0.99 6.15, (0 0.0000 0.05 0.09 0.05 0.09 0.05 0.09 0.25 0.69 0.25 0.81 0.69 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 | if = 6 (F 1) 34 30 21 30 69 35 20 239 if = 6 (F 20 239 if = 6 (F 20 239 35 20 20 35 20 20 9 35 20 20 9 35 20 20 9 35 20 20 9 35 20 20 9 35 20 20 9 35 20 20 9 35 20 20 20 20 20 20 20 20 20 20 20 20 20 | 3 3.64 3.2 2.23 3 2.8 2.2 2 = 0.01) 1.5 2.6 0.7 3 3.69 1.85 = 0.78); (P = 0.00 | 0.48 0.73 0.25 2.1 0.5 1.89 0.89 ; I ² = 0 0.24 0.5 0.69 0.25 0.9 0.67 I ² = 0 9 0.027; I | 34 300 69 35 20 239 33% 34 21 30 69 35 20 239 35 20 209 % 4 1059 *= 55% | 5.1% 2.2% 3.9% 0.4% 6.4% 0.5% 1.0% 19.5% 7.8% 2.4% 7.8% 1.9% 1.8% 24.4% | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] -0.60 [-0.84, -0.36] -1.40 [-2.32, -0.48] -0.50 [-0.63, -0.37] -0.70 [-1.54, 0.14] -0.45 [-1.03, 0.13] -0.52 [-0.72, -0.33] -0.50 [-0.72, -0.33] -0.50 [-0.80, -0.20] -0.60 [-0.95, -0.25] -0.50 [-0.58, -0.42] -0.54 [-0.94, -0.14] -0.20 [-0.62, 0.22] -0.48 [-0.54, -0.43] | |
| Heterogeneity: $Tau^2 = 0.03$; Test for overall effect: $Z = 6.2$ 4.1.4 At 12 hour B. Altıparmak, et al., 2019 Engineer et al., 2022 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 Tulgar, et al., 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.03; Test for overall effect: $Z = 5.3$ 4.1.5 At 24 hour B. Altıparmak, et al., 2019 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 Tulgar, et al., 2021 Meterogeneity: Tau ² = 0.00; Test for overall effect: $Z = 16$ Test for subgroup difference | 22 (P < 1 2.8 2.9 2.6 0.83 2.5 2.1 1.75 Chi ² = 1 30 (P < 1 1.03 2.1 0.1 2.5 3.15 1.65 Chi ² = 2 5.97 (P < Chi ² = 6 5.95 (P < | 0.24 0.73 0.5 1.5 0.25 1.7 0.99 6.15, (0 0.0000 0.05 0.09 0.05 0.09 0.05 0.09 0.25 0.69 0.25 0.81 0.69 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 | if = 6 (F 1) 34 30 21 30 69 35 20 239 if = 6 (F 20 239 if = 6 (F 20 239 35 20 20 35 20 20 9 35 20 20 9 35 20 20 9 35 20 20 9 35 20 20 9 35 20 20 9 35 20 20 9 35 20 20 20 20 20 20 20 20 20 20 20 20 20 | 3 3.64 3.2 2.23 3 2.8 2.2 2 = 0.01) 1.5 2.6 0.7 3 3.69 1.85 = 0.78); (P = 0.00 | 0.48 0.73 0.25 2.1 0.5 1.89 0.89 ; I ² = 0 0.24 0.5 0.69 0.25 0.9 0.67 I ² = 0 9 0.027; I | 34 300 69 35 20 239 33% 34 21 30 69 35 20 239 35 20 209 % 4 1059 *= 55% | 5.1% 2.2% 3.9% 0.4% 6.4% 0.5% 1.0% 19.5% 7.8% 2.4% 7.8% 1.9% 1.8% 24.4% | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] -0.60 [-0.84, -0.36] -1.40 [-2.32, -0.48] -0.50 [-0.63, -0.37] -0.70 [-1.54, 0.14] -0.45 [-1.03, 0.13] -0.52 [-0.72, -0.33] -0.50 [-0.72, -0.33] -0.50 [-0.80, -0.20] -0.60 [-0.95, -0.25] -0.50 [-0.58, -0.42] -0.54 [-0.94, -0.14] -0.20 [-0.62, 0.22] -0.48 [-0.54, -0.43] | |
| Heterogeneity: $Tau^2 = 0.03$; Test for overall effect: $Z = 6.2$ 4.1.4 At 12 hour B. Altıparmak, et al., 2019 Engineer et al., 2022 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2019 Subtotal (95% CI) Heterogeneity: Tau ² = 0.03; Test for overall effect: $Z = 5.2$ 4.1.5 At 24 hour B. Altıparmak, et al., 2019 Ibrahim M., 2020 Lingaraj S et al., 2021 Mounika et al., 2023 Routray et al., 2020 Tulgar, et al., 2021 Mounika et al., 2023 Routray et al., 2020 Tulgar, et al., 2020 | 22 (P < 1 2.8 2.9 2.6 0.83 2.5 2.1 1.75 Chi ² = 1 30 (P < 1 1.03 2.1 0.1 2.5 3.15 1.65 Chi ² = 2 0.97 (P < Chi ² = 6 0.95 (P < es: Chi ² | 0.24 0.73 0.5 1.5 0.25 1.7 0.99 6.15, (0.0000 0.25 0.81 0.69 0.25 0.81 0.69 0.25 0.81 0.69 0.25 0.81 0.69 0.25 0.44 0.50, df 0.25 0.44 0.50, df 0.25 0.44 0.50, df 0.25 0.44 0.50, df 0.50, df | if = 6 (F (F) 1) 34 30 21 30 69 35 20 239 if = 6 (F) 34 21 30 69 35 20 239 if = 6 (F) 20 209 = 5 (P) 1059 105 | 3 3.64 3.2 2.23 3 2.8 2.2 9 = 0.01) 1.5 2.6 0.7 3 3.69 1.85 = 0.78); (P = 0.00 (P = 0.4 | 0.48 0.73 0.25 2.1 0.5 1.89 0.89 ; ² = 6 0.25 0.69 0.25 0.9 0.25 0.9 0.27 ² = 0 9 0.27 () 1 ² = 0 9 0.27 0.29 () 1 ² = 0 9 0.27 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 | 34 300 69 35 20 239 35 20 239 35 20 209 % 4 1059 * = 55% | 5.1% 2.2% 3.9% 0.4% 6.4% 0.5% 1.0% 19.5% 7.8% 2.4% 7.8% 1.9% 1.8% 24.4% | -0.20 [-0.38, -0.02] -0.74 [-1.11, -0.37] -0.60 [-0.84, -0.36] -1.40 [-2.32, -0.48] -0.50 [-0.63, -0.37] -0.70 [-1.54, 0.14] -0.45 [-1.03, 0.13] -0.52 [-0.72, -0.33] -0.50 [-0.72, -0.33] -0.50 [-0.80, -0.20] -0.60 [-0.95, -0.25] -0.50 [-0.58, -0.42] -0.54 [-0.94, -0.14] -0.20 [-0.62, 0.22] -0.48 [-0.54, -0.43] | |

4 Discussion

To the best of our knowledge, this is the first systematic review and meta-analysis that compares the efficacy of erector spinae plane block and transversus abdominis plane block for postoperative pain relief after laparoscopic cholecystectomy (see Figure 7). According to our study, the ESP block was more effective in reducing pain severity scores at all measured time points after the surgery, both at rest and during movement, except for the 1st and 6th h of pain scores during movement. In addition, it resulted in lower morphine equivalent consumption during the first 24 h than the TAP block following LC. The ESP block also extended the time before the first request for additional pain relief compared to the TAP block.

| Study or Subgroup | E Mean | SPB | Total | T. Mean | APB | Total | Woight | Mean Difference IV. Random, 95% CI | Mean Difference IV. Random, 95% Cl |
|---|-----------|-------|-------------|------------|---------------------|-----------------|--------|---------------------------------------|--|
| 1.1.1 At 1 hr | Weall | 30 | Total | Weall | 30 | Total | weight | IV, Rahuolii, 95% Ci | IV, Kalidolli, 95% Ci |
| B. Altıparmak, et al., 2019 | 2 | 0.5 | 34 | 2.8 | 0.31 | 34 | 7.1% | -0.80 [-1.00, -0.60] | _ _ |
| Routray et al., 2020 | 1.94 | 2.1 | 35 | 2.98 | | 35 | 1.0% | -1.04 [-2.05, -0.03] | · |
| Tulgar, et al., 2019 | 1.65 | | 20 | 1.6 | 0.6 | 20 | 4.4% | 0.05 [-0.32, 0.42] | |
| Subtotal (95% CI) | | | 89 | | | 89 | 12.4% | -0.53 [-1.22, 0.15] | |
| Heterogeneity: Tau ² = 0.29; Test for overall effect: Z = 1.6 | | | f= 2 (F | ' = 0.000 |)3); I² = | : 88% | | | |
| 1.1.2 At 2 hr | | | | | | | | | |
| B. Altıparmak, et al., 2019 | 2.4 | 0.25 | 34 | 31 | 0.25 | 34 | 8.4% | -0.70 [-0.82, -0.58] | - |
| H. Ozdemir et al., 2021 | 2.3 | 1.2 | 30 | 3.4 | 1.1 | 30 | 2.4% | -1.10 [-1.68, -0.52] | ← |
| Ibrahim M., 2020 | 2.7 | | 21 | | 0.25 | 21 | 7.9% | -0.60 [-0.75, -0.45] | |
| Subtotal (95% CI) | | | 85 | | | 85 | 18.7% | -0.68 [-0.81, -0.54] | ◆ |
| Heterogeneity: Tau ² = 0.01; Test for overall effect: Z = 9.9 | | | | = 0.21); | ² = 37' | % | | | |
| 1.1.3 At 6 h | | | | | | | | | |
| H. Ozdemir et al., 2021 | 0.9 | 0.8 | 30 | 1.8 | 0.8 | 30 | 3.9% | -0.90 [-1.30, -0.50] | |
| Ibrahim M., 2020 | 3.1 | 0.25 | 21 | 3.4 | 0.25 | 21 | 7.9% | -0.30 [-0.45, -0.15] | |
| Routray et al., 2020 | 2.15 | 1.58 | 35 | 3.1 | 1.02 | 35 | 2.2% | -0.95 [-1.57, -0.33] | |
| Tulgar, et al., 2019 | 2.45 | 0.6 | 20 | 2.15 | 1.18 | 20 | 2.4% | 0.30 [-0.28, 0.88] | |
| Subtotal (95% CI) | | | 106 | | | 106 | 16.4% | -0.46 [-0.92, -0.00] | |
| Heterogeneity: Tau ² = 0.17; Test for overall effect: Z = 1.9 | | | f = 3 (F | ' = 0.001 |); ² = | 81% | | | |
| 1.1.4 At 12 h | | | | | | | | | |
| B. Altiparmak, et al., 2019 | 2.7 | 0.25 | 34 | 3.25 | 0.5 | 34 | 7.2% | -0.55 [-0.74, -0.36] | _ |
| H. Ozdemir et al., 2021 | 0.5 | 0.5 | 30 | 1.2 | 0.8 | 30 | 4.8% | -0.70 [-1.04, -0.36] | |
| Ibrahim M., 2020 | 3.2 | 0.25 | 21 | 3.6 | 0.3 | 21 | 7.6% | -0.40 [-0.57, -0.23] | |
| Routray et al., 2020 | 2.54 | | 35 | | 1.02 | 35 | 2.1% | -0.56 [-1.19, 0.07] | |
| Tulgar, et al., 2019 | 2.1 | 0.55 | 20 | 2.5 | 1.05 | 20 | 2.9% | -0.40 [-0.92, 0.12] | |
| Subtotal (95% CI) | | | 140 | | | 140 | 24.6% | -0.49 [-0.60, -0.38] | • |
| Heterogeneity: Tau ² = 0.00; Test for overall effect: Z = 8.6 | | | | = 0.53);1 | I ² = 0% |) | | | |
| 1.1.5 At 24 h | | | | | | | | | |
| B. Altıparmak, et al., 2019 | 1.2 | 0.06 | 34 | 1.6 | 0.25 | 34 | 8.8% | -0.40 [-0.49, -0.31] | - |
| H. Ozdemir et al., 2021 | 0.1 | 0.3 | 30 | 0.6 | 0.5 | 30 | 6.9% | -0.50 [-0.71, -0.29] | |
| Ibrahim M., 2020 | 2.8 | 0.5 | 21 | 3.2 | 0.5 | 21 | 5.3% | -0.40 [-0.70, -0.10] | _ - |
| Routray et al., 2020 | 3.1 | 1.14 | 35 | 3.2 | 1.8 | 35 | 1.8% | -0.10 [-0.81, 0.61] | |
| Tulgar, et al., 2019 | 2 | 0.56 | 20 | 2.3 | 0.47 | 20 | 5.0% | -0.30 [-0.62, 0.02] | |
| Subtotal (95% CI) | | | 140 | | | 140 | 27.8% | -0.40 [-0.48, -0.33] | ◆ |
| Heterogeneity: Tau ² = 0.00; Test for overall effect: Z = 10 | | | | = 0.75);1 | I ² = 0% | , | | | |
| Total (95% CI) | | | 560 | | | 560 | 100.0% | -0.50 [-0.61, -0.40] | ◆ |
| Heterogeneity: Tau ² = 0.03; Test for overall effect: Z = 9.3 Test for subgroup difference | 38 (P < 0 | .0000 | f=19(I) | | | I ² = 71 | % | | -1 -0.5 0 0.5 1 Favours [ESPB] Favours [TAPB] |
| IRE 4 | | | | | | | | | |
| | | | | | | | | | |
| toperative pain scores at di | fforont + | imer | ainte - | in movie | mont | ofter | C | | |



| | E | SPB | | Т | APB | | | Mean Difference | Mean Difference | |
|---------------------------------------|-----------|-------|-------------------|-----------|----------|--------|----------|-------------------------|-------------------------------|---|
| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | IV, Random, 95% CI | IV, Random, 95% CI | |
| Engineer et al., 2022 | 642 | 444 | 30 | 228 | 278.4 | 30 | 4.4% | 414.00 [226.47, 601.53] | | * |
| H. Ozdemir et al., 2021 | 107.5 | 21.8 | 32 | 76.1 | 9.6 | 32 | 34.0% | 31.40 [23.15, 39.65] | • | |
| lbrahim M., 2020 | 384 | 55 | 21 | 343 | 51 | 21 | 28.7% | 41.00 [8.92, 73.08] | | |
| Routray et al., 2020 | 360.34 | 8.94 | 35 | 280.51 | 45.66 | 35 | 32.9% | 79.83 [64.42, 95.24] | | |
| Total (95% CI) | | | 118 | | | 118 | 100.0% | 66.86 [24.85, 108.86] | | |
| Heterogeneity: Tau ² = 133 | | - | -100 -50 0 50 100 | | | | | | | |
| Test for overall effect: Z = | 3.12 (P = | 0.002 |) | | | | | | Favours [ESPB] Favours [TAPB] | |
| GURE 6 | | | | | | | | | | |
| orest plot diagram of first a | analgesia | requ | est tim | ie in mir | uites he | otweer | n arouns | after I C | | |
| orest plot diagram or mista | anatyesia | ilequ | escuri | | iutes be | etweer | rgioups | arter LC. | | |

| 10. 10 D. 0 | ESP | | TAP | U I | | Risk Ratio | Risk Ratio |
|---|------------------------|---------|---------------|----------------------|-----------|---------------------|---|
| Study or Subgroup | Events | Total | Events | Total | Weight | M-H, Random, 95% Cl | M-H, Random, 95% Cl |
| B. Altıparmak, et al., 2019 | 2 | 34 | 5 | 34 | 18.8% | 0.40 [0.08, 1.92] | |
| lbrahim M., 2020 | 4 | 21 | 4 | 21 | 24.2% | 1.00 [0.29, 3.48] | |
| Lingaraj Sahu et al., 2021 | 6 | 30 | 3 | 30 | 23.4% | 2.00 [0.55, 7.27] | |
| Mounika et al., 2023 | 0 | 69 | 9 | 69 | 8.0% | 0.05 (0.00, 0.89) | ← → → → → → → → → → → → → → → → → → → → |
| Routray et al., 2020 | 4 | 35 | 6 | 35 | 25.6% | 0.67 [0.21, 2.16] | |
| Total (95% CI) | | 189 | | 189 | 100.0% | 0.70 [0.29, 1.70] | - |
| Total events | 16 | | 27 | | | | |
| Heterogeneity: Tau ² = 0.43; | Chi ² = 7.1 | 3, df = | 4 (P = 0.1 | 3); I ^z = | 44% | | 0.01 0.1 1 10 100 |
| Test for overall effect: $Z = 0$. | 78 (P = 0.4 | 43) | | | | | Favours [ESPB] Favours [TAPB] |
| JRE 7 | | | | | | | |
| est plot diagram showing th | | | at a la avati | | cop and y | omiting after IC | |

There were no significant differences in the incidence of postoperative nausea and vomiting. However, it is important to interpret the findings of this meta-analysis with caution, as the available data are of moderate quality and quantity.

The mean difference in pain scores, as measured on a 0-10 point analog scale, during rest and on movement consistently remained close to 0.5 cm at all postoperative times. Although this difference was statistically significant, it was not considered clinically relevant. It is worth mentioning that Bahreini et al. (30) have suggested that for a change in pain severity to be considered clinically significant, there should be a difference of more than 1.65 out of 11 on the NRS or 16.55 out of 100 on the VAS.

Consistent with our findings, a recent systematic review and meta-analysis (17) that included 10 randomized controlled trials (RCTs) with 570 patients who underwent various types of abdominal surgeries found that the ESP block significantly reduced pain scores at all-time points and opioid consumption during the first 24 h postoperatively compared to the TAP block; however, the observed difference was not clinically significant. Additionally, another recent Cochrane review (31) that included 64 studies found no clinically significant reduction in postoperative pain at rest 24 h after surgery in patients who received the ESP block. Another recent meta-analysis (32) compared different nerve blocks, including TAP, ESP, quadratus lumborum, paravertebral, and rectus sheath blocks, to provide effective postoperative analgesia for LC; however, our study is the first to compare ESP and TAP blocks for LC.

Although the ESP block has limited clinical significance in reducing pain scores, it does reduce opioid consumption, prolongs analgesia duration, and has minimal block-related adverse events (33). Our meta-analysis has shown that the ESP block can significantly decrease morphine cumulative consumption and enhance the first analgesia request time compared to the TAP block.

While a laparoscopic cholecystectomy (LC) is considered a minimally invasive procedure compared to an open cholecystectomy, it is still associated with significant postoperative pain that can increase readmission rates and hospital stays (4-6). Acute postoperative pain resulting from LC includes somatic, visceral, and referred pain (2, 3). Typically, patients experience the most intense pain within the first 24 h after surgery, with visceral pain being the primary type, followed by somatic pain (34). Additionally, patients who experience more intense visceral pain face a higher risk of developing chronic pain after undergoing LC (35).

In this context, the ESP block may prove to be more effective than the TAP block in treating somatic and visceral pain. The TAP block is limited to treating pain originating solely from somatic sensory, whereas the ESP block offers broader pain control (36). The mechanism of visceral analgesia achieved by ESPB is not yet fully understood, although limited evidence supports the theory that local anesthetics spread anteriorly into the paravertebral space, thereby blocking visceral sensory (37). Unlike the TAP block, the efficacy of the ESP block in blocking visceral pain pathways is subject to scrutiny and requires further research.

This meta-analysis has several limitations that should be noted. Like most systematic reviews, there is heterogeneity among the included studies. This heterogeneity is likely due to the various intraoperative and postoperative analgesic protocols used. Blocks were performed in different ways, either in awake states or before surgical incisions under anesthesia, and we combined all these approaches. Although all the trials included in this study were of high quality, they had small sample sizes, which may impact the level of evidence presented. Additionally, a variety of local anesthetic drugs, volumes, and dosages, with or without adjuvants, were used across the studies, which could have influenced the results. Finally, due to a lack of access, we used the risk of bias tool 1 (ROB 1) instead of the risk of bias tool 2 (ROB 2).

Despite these limitations, this meta-analysis is the first to pool results from recent randomized controlled trials published within the last 5 years, comparing the efficacy of erector spinae plane and transversus abdominis plane blocks for pain control following laparoscopic cholecystectomy.

5 Conclusion

The ESP block effectively reduces postoperative pain scores at rest and during movement. However, it has not yet reached a level of clinical significance. Furthermore, the use of the ESP block leads to a significant reduction in morphine equivalent consumption and improves the time at which patients first request analgesia after laparoscopic cholecystectomy. We suggest clinicians consider using an ultrasound-guided ESP block as an effective technique for postoperative pain relief in patients undergoing LC.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

DZ: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. TTa: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing. SE: Conceptualization, Data curation,

References

1. Barazanchi AWH, MacFater WS, Rahiri JL, Tutone S, Hill AG, Joshi GP. Evidencebased management of pain after laparoscopic cholecystectomy: a PROSPECT review update. *Br J Anaesth.* (2018) 121:787–803. doi: 10.1016/j.bja.2018.06.023

2. Yilmaz H, Arun O, Apiliogullari S, Acar F, Alptekin H, Calisir A, et al. Effect of laparoscopic cholecystectomy techniques on postoperative pain: a prospective randomized study. *J Korean Surg Soc.* (2013) 85:149–53. doi: 10.4174/jkss.2013.85.4.149

3. Blichfeldt-Eckhardt MR, Ording H, Andersen C, Licht PB, Toft P. Early visceral pain predicts chronic pain after laparoscopic cholecystectomy. *Pain*. (2014) 155:2400–7. doi: 10.1016/j.pain.2014.09.019

4. Mitra S, Khandelwal P, Roberts K, Kumar S, Vadivelu N. Pain relief in laparoscopic cholecystectomy--a review of the current options. *Pain Pract.* (2012) 12:485–96. doi: 10.1111/j.1533-2500.2011.00513.x

 Mak MHW, Chew WL, Junnarkar SP, Woon WWL, Low JK, Huey TCW, et al. Patient reported outcomes in elective laparoscopic cholecystectomy. *Ann Hepatobiliary Pancreat Surg.* (2019) 23:20–33. doi: 10.14701/ahbps.2019.23.1.20 Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Writing – original draft, Writing – review & editing. TTi: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Acknowledgments

We thank Wolkite University's specialist medical library staff for helping us develop a search strategy.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2024.1399253/ full#supplementary-material

6. Lockett MA, Ward RC, McCauley JL, Taber DJ, Gebregziabher M, Cina RA, et al. New chronic opioid use in Medicaid patients following cholecystectomy. *Surg Open Sci.* (2022) 9:101–8. doi: 10.1016/j.sopen.2022.05.009

7. Zewdu D, Tantu T, Olana M, Teshome D. Effectiveness of wound site infiltration for parturients undergoing elective cesarean section in an Ethiopian hospital: a prospective cohort study. *Ann Med Surg.* (2021) 64:64. doi: 10.1016/j. amsu.2021.102255

8. Protic M, Veljkovic R, Bilchik AJ, Popovic A, Kresoja M, Nissan A, et al. Prospective randomized controlled trial comparing standard analgesia with combined intraoperative cystic plate and port-site local anesthesia for post-operative pain management in elective laparoscopic cholecystectomy. *Surg Endosc.* (2017) 31:704–13. doi: 10.1007/ s00464-016-5024-5

9. Loizides S, Gurusamy KS, Nagendran M, Rossi M, Guerrini GP, Davidson BR. Wound infiltration with local anaesthetic agents for laparoscopic cholecystectomy. *Cochrane Database Syst Rev.* (2014) 3:CD007049. doi: 10.1002/14651858.CD007049. pub2 10. Sun C, He Z, Feng B, Huang Y, Liu D, Sun Z. Effect of intraperitoneal instillation of Dexmedetomidine with local anesthetics in laparoscopic cholecystectomy: a systematic review and Meta-analysis of randomized trials. *Surg Laparosc Endosc Percutan Tech.* (2024) 34:222–32. doi: 10.1097/SLE.000000000001262

11. Picard L, Duceau B, Cambriel A, Voron T, Makoudi S, Tsai AS, et al. Risk factors for prolonged time to hospital discharge after ambulatory cholecystectomy under general anaesthesia. A retrospective cohort study. *Int J Surg.* (2022) 104:106706. doi: 10.1016/j.ijsu.2022.106706

12. Hwang BY, Kwon JY, Kim E, Lee DW, Kim TK, Kim HK. Oxycodone vs. fentanyl patient-controlled analgesia after laparoscopic cholecystectomy. *Int J Med Sci.* (2014) 11:658–62. doi: 10.7150/ijms.8331

13. Aga A, Abrar M, Ashebir Z, Seifu A, Zewdu D, Teshome D. The use of perineural dexamethasone and transverse abdominal plane block for postoperative analgesia in cesarean section operations under spinal anesthesia: an observational study. *BMC Anesthesiol.* (2021) 21:1–8. doi: 10.1186/s12871-021-01513-4

14. Oksar M, Koyuncu O, Turhanoglu S, Temiz M, Oran MC. Transversus abdominis plane block as a component of multimodal analgesia for laparoscopic cholecystectomy. *J Clin Anesth.* (2016) 34:72–8. doi: 10.1016/j.jclinane.2016.03.033

15. Tan H, Huang HF, Lu IC. Erector spinae plane block enhances multimodal analgesia for laparoscopic cholecystectomy. *J Investig Surg.* (2022) 35:878–9. doi: 10.1080/08941939.2021.1943573

16. Daghmouri MA, Akremi S, Chaouch MA, Mesbahi M, Amouri N, Jaoua H, et al. Bilateral erector spinae plane block for postoperative analgesia in laparoscopic cholecystectomy: a systematic review and Meta-analysis of randomized controlled trials. *Pain Pract.* (2021) 21:357–65. doi: 10.1111/papr.12953

17. Liheng L, Siyuan C, Zhen C, Changxue W. Erector spinae plane block versus transversus abdominis plane block for postoperative analgesia in abdominal surgery: a systematic review and Meta-analysis. *J Investig Surg.* (2022) 35:1711–22. doi: 10.1080/08941939.2022.2098426

18. Engineer SR, Devanand A, Kulkarni M. Comparative study of the efficacy of ultrasound-guided erector spinae block and oblique subcostal transversus abdominis plane block for postoperative analgesia after laparoscopic cholecystectomy. Ain-shams. *J Anesthesiol.* (2022) 14:285. doi: 10.1186/s42077-022-00285-4

19. Sahu L, Sk B, Gc S, Saxena S, Priyadarshini S, Rk S. Comparison of analgesic efficacy of erector spinae and oblique subcostal transverse abdominis plane block in laparoscopic cholecystectomy. *J Clin Diagn Res.* (2021) 15:15380. doi: 10.7860/JCDR/2021/50795.15380

20. Mounika V, Sahu L, Mishra K, Mohapatra PS. A comparative evaluation of postoperative pain management using erector spinae plane block and oblique transverse abdominis plane block in patients undergoing laparoscopic cholecystectomy. *Cureus*. (2023) 15:e35750. doi: 10.7759/cureus.35750

21. Altıparmak B, Korkmaz Toker M, Uysal AI, Kuşçu Y, Gümüş DS. Ultrasound-guided erector spinae plane block versus oblique subcostal transversus abdominis plane block for postoperative analgesia of adult patients undergoing laparoscopic cholecystectomy: randomized, controlled trial. *J Clin Anesth.* (2019) 57:31–6. doi: 10.1016/j.jclinane.2019.03.012

22. Ozdemir H, Araz C, Karaca O, Turk E. Comparison of ultrasound-guided erector spinae plane block and subcostal transversus abdominis plane block for postoperative analgesia after laparoscopic cholecystectomy: a randomized. *Controlled Trial J Invest Surg.* (2022) 35:870–7. doi: 10.1080/08941939.2021.1931574

23. Tulgar S, Kapakli MS, Kose HC, Senturk O, Selvi O, Serifsoy TE, et al. Evaluation of ultrasound-guided erector spinae plane block and oblique subcostal transversus abdominis plane block in laparoscopic cholecystectomy: randomized, controlled. *Prospect Study Anesth Essays Res.* (2019) 13:50–6. doi: 10.4103/aer.AER_194_18

24. Routray SS, Mohanty R, Pradhan K, Pani S. Evaluation of efficacy of ultrasound guided erector spinae plane block and oblique subcostal transversus abdominis plane block for postoperative analgesia in laparoscopic cholecystectomy. *Panacea J Med Sci.* (2020) 10:128–34. doi: 10.18231/j.pjms.2020.028

25. Ibrahim M. Erector spinae plane block in laparoscopic cholecystectomy, is there a difference? A randomized controlled trial. *Anesthes Essays Res.* (2020) 14:119–26. doi: 10.4103/aer.AER_144_19

26. Wang W, Wang L, Gao Y. A Meta-analysis of randomized controlled trials concerning the efficacy of transversus abdominis plane block for pain control after laparoscopic cholecystectomy. *Front Surg.* (2021) 8:700318. doi: 10.3389/ fsurg.2021.700318

27. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev.* (2015) 4:1. doi: 10.1186/2046-4053-4-1

28. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol.* (2014) 14:1–13. doi: 10.1186/1471-2288-14-135

29. Committee JF. British national formulary Pharmaceutical Press (2012) 64.

30. Bahreini M, Safaie A, Mirfazaelian H, Jalili M. How much change in pain score does really matter to patients? *Am J Emerg Med.* (2020) 38:1641–6. doi: 10.1016/j. ajem.2019.158489

31. Oostvogels L, Weibel S, Meißner M, Kranke P, Meyer-Frießem CH, Pogatzki-Zahn E, et al. Erector spinae plane block for postoperative pain. *Cochrane Database Syst Rev.* (2024) 2024:13763. doi: 10.1002/14651858.CD013763.pub3

32. De Cassai A, Sella N, Geraldini F, Tulgar S, Ahiskalioglu A, Dost B, et al. Singleshot regional anesthesia for laparoscopic cholecystectomies: a systematic review and network meta-analysis. *Korean J Anesthesiol.* (2023) 76:34–46. doi: 10.4097/kja.22366

33. Tulgar S, Selvi O, Senturk O, Serifsoy TE, Thomas DT. Ultrasound-guided erector spinae plane block: indications, complications, and effects on acute and chronic pain based on a single-center experience. *Cureus*. (2019) 11:e3815. doi: 10.7759/cureus.3815

34. Boezaart AP, Smith CR, Chembrovich S, Zasimovich Y, Server A, Morgan G, et al. Visceral versus somatic pain: an educational review of anatomy and clinical implications. *Reg Anesth Pain Med.* (2021) 46:629–36. doi: 10.1136/rapm-2020-102084

35. Lee H, Askar A, Makanji D, Ranjha K, Karki BB, Courcol J, et al. The incidence of post cholecystectomy pain (PCP) syndrome at 12 months following laparoscopic cholecystectomy: a prospective evaluation in 200 patients. *Scand J Pain*. (2024) 24:67. doi: 10.1515/sjpain-2023-0067

36. Schwartzmann A, Peng P, Maciel MA, Forero M. Mechanism of the erector spinae plane block: insights from a magnetic resonance imaging study. *Can J Anaesth.* (2018) 65:1165–6. doi: 10.1007/s12630-018-1187-y

37. Kwon HM, Kim DH, Jeong SM, Choi KT, Park S, Kwon HJ, et al. Does erector spinae plane block have a visceral analgesic effect?: a randomized controlled trial. *Sci Rep.* (2020) 10:8389. doi: 10.1038/s41598-020-65172-0